Inserting peritoneal dialysis catheters using a bedside technique

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PREDICT project focuses on the insertion of peritoneal dialysis (PD) catheters using a percutaneous strategy, which can be performed at the bedside under local anesthesia. This method is particularly beneficial for patients who cannot undergo general anesthesia due to severe heart failure or other health issues. The study aims to gather demographic and clinical data from adult patients requiring PD catheter insertion between March 2023 and March 2026. By comparing this approach to traditional laparoscopic techniques, the project seeks to expand access to PD for more patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years
* Percutaneous PD catheter insertion between March 1st 2023 and March 1st 2026 Patients can be included 4 weeks before until 12 weeks after PD catheter insertion

Exclusion Criteria:

* Inability to provide informed consent
* Life expectancy \< 3 months

Where it's running

• Universitair Ziekenhuis Brussel
  Brussels, Belgium Recruiting
• UMC Utrecht
  Utrecht, Netherlands Recruiting

Study contacts

• Study coordinator: Karlien François, MD PhD
• Email: Karlien.Francois@uzbrussel.be
• Phone: +324776055

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Staged kidney implantation with hypothermic oxygenated machine perfusion during combined heart and kidney transplants

  This trial will test whether keeping the donor kidney on oxygenated machine perfusion and implanting it later helps adults who are receiving both a heart and a kidney transplant.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT06877169

• Moda-flx Hemodialysis System for clinic and at-home use

  This trial will test whether the Moda-flx Hemodialysis System can be used safely and effectively by trained professionals in clinics and by trained patients and care partners at home for adults with end-stage kidney disease.

  Recruiting at 5 sites Diality Inc. · San Dimas, California and 4 other locations · NCT06613568

• Comparing two beta blockers for heart health in dialysis patients

  This study is testing which beta blocker, metoprolol or carvedilol, is better for heart health in veterans on dialysis to see if it can help them live longer and feel better.

  Recruiting at 12 sites Phase 3 VA Office of Research and Development · Long Beach, California and 17 other locations · NCT05931276

• Comparing Incremental Hemodialysis to Conventional Hemodialysis

  This study is testing if a new way of doing hemodialysis called incremental hemodialysis can help people with end-stage kidney disease feel better and have fewer hospital visits compared to the standard method.

  Recruiting at 10 sites Wake Forest University Health Sciences · Jacksonville, Florida and 9 other locations · NCT05828823

• Monitoring symptoms in patients undergoing hemodialysis

  This study is testing a new system that helps patients on hemodialysis report their symptoms more easily to see if it improves their care compared to regular check-ups.

  Recruiting University of Pennsylvania · Waltham, Massachusetts · NCT05738330

• Investigating the safety and mechanisms of SGLT2 inhibitors in patients on peritoneal dialysis

  This study is testing if a diabetes medication called empagliflozin is safe and helpful for people on peritoneal dialysis who still have some kidney function, to see if it can protect their heart and kidneys.

  Recruiting Phase 3 University Health Network, Toronto · Toronto, Ontario · NCT05715814

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.